A phase IIIB study to evaluate the mechanism of action of 1.0 mg/kg subcutaneously administered efalizumab in adults with moderate to severe plaque psoriasis who are candidates for systemic therapy
Phase of Trial: Phase III
Latest Information Update: 24 Nov 2014
At a glance
- Drugs Efalizumab (Primary)
- Indications Plaque psoriasis
- Focus Therapeutic Use
- Sponsors Genentech
- 13 Dec 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 19 Sep 2009 New trial record.